ConductScience.org, home

Paper914

Overview: maintenance therapy in psychiatry: I. Schizophrenia.

Davis JM. Am J Psychiatry, 1975. Cited by 394 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Papers, record 914. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/914

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overview: maintenance therapy in psychiatry: I. Schizophrenia.
PubMed
Journal
Am J Psychiatry
PubMed
Year
1975
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Review
PubMed
Citations, by iCite
394
iCite
Relative citation ratio, by iCite
19.6
iCite
Revised in PubMed
2013-11-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Davis JMJ M

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
SchizophreniaMajor topic
Clinical Trials as Topic
Drug Evaluation
Female
Fluphenazine
Humans
Male
Recurrence
Research Design
Time Factors

Source PubMed

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 394 citations.

PMIDTitleJournalYearIn PapersSource
42,157,201Psychiatric hospitalization and rehospitalization among children and adolescents: evidence from 10-years electronic records in Beijing, China.BMC Psychiatry2026https://conductscience.org/library/papers/42157201PubMed
41,288,687Clinical outcomes in first-episode schizophrenia: identifying predictors of relapse.Soc Psychiatry Psychiatr Epidemiol2026https://conductscience.org/library/papers/41288687PubMed
39,144,771Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts.Schizophr Bull Open2022https://conductscience.org/library/papers/39144771PubMed
34,768,521Risk Factors for Revolving Door in Children and Adolescents with Psychiatric Disorders.J Clin Med2021https://conductscience.org/library/papers/34768521PubMed
32,840,872Maintenance treatment with antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2020https://conductscience.org/library/papers/32840872PubMed
31,006,114Haloperidol discontinuation for people with schizophrenia.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/31006114PubMed
26,508,952Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study.Psychiatry Investig2015https://conductscience.org/library/papers/26508952PubMed
25,290,157Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25290157PubMed
25,177,834Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25177834PubMed
25,087,165Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25087165PubMed
25,007,358Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25007358PubMed
25,003,310Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/25003310PubMed
24,596,880Rivers of evidence.Int J Health Policy Manag2013https://conductscience.org/library/papers/24596880PubMed
22,909,285Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.BMC Psychiatry2012https://conductscience.org/library/papers/22909285PubMed
22,889,923Another view of the history of antipsychotic drug discovery and development.Mol Psychiatry2012https://conductscience.org/library/papers/22889923PubMed
21,286,547The stages of schizophrenia and their management.Can Fam Physician1982https://conductscience.org/library/papers/21286547PubMed
19,176,470Psychosocial treatments to promote functional recovery in schizophrenia.Schizophr Bull2009https://conductscience.org/library/papers/19176470PubMed
18,748,785Psychiatry-epitomes of progress: tardive dyskinesia.West J Med1981https://conductscience.org/library/papers/18748785PubMed
18,245,059Cochrane Schizophrenia Group.Schizophr Bull2008https://conductscience.org/library/papers/18245059PubMed
17,253,586Cessation of medication for people with schizophrenia already stable on chlorpromazine.Cochrane Database Syst Rev2007https://conductscience.org/library/papers/17253586PubMed

See all 45 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/914

GET https://conductscience.org/api/papers/v1/914/cited_by?page=2